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Abstract 25 
Introduction  26 
Pseudomonas aeruginosa is an important respiratory pathogen in cystic fibrosis (CF), which is 27 
associated with an accelerated decline in lung function, frequent pulmonary exacerbations and 28 
increased mortality.  P. aeruginosa produces intercellular signalling molecules including 2-alkyl-4-29 
quinolones (AQs), which regulate virulence factor production and biofilm formation in the CF 30 
airways. Studies have shown that AQs are detectable in the sputum and plasma of adults with CF 31 
and chronic pulmonary P. aeruginosa. 32 
Aim 33 
We tested the hypothesis that the presence of six AQs in plasma or sputum obtained from adults 34 
with CF was associated with long term adverse clinical outcomes. 35 
Methodology 36 
 We analysed clinical data over an 8-year follow period for 90 people with CF who had previously 37 
provided samples for AQ analysis at clinical stability.  38 
The primary outcome was all cause mortality or lung transplantation. Secondary outcomes were 39 
rate of lung function decline and number of intravenous (IV) antibiotic days for pulmonary 40 
exacerbations.  41 
Results 42 
There was no statistical association between the presence of any of the six measured AQs and the 43 
primary outcomes or the secondary outcome of decline in lung function. One of the 6 AQs was 44 
associated with IV antibiotic usage. The presence of 2-nonyl-3-hydroxy-4(1H)-quinolone (C9-PQS) 45 
in sputum was associated with an increase in the number of IV antibiotic days in the follow up period 46 
(Mann-Whitney; p=0.011).  47 
 48 
 49 
Conclusion 50 
Further investigation to confirm the hypothesis that C9-PQS may be associated with increased 51 
antibiotic usage for pulmonary exacerbations is warranted as AQ-dependent signalling is a potential 52 
future target for anti-virulence therapies.  53 
 54 
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Introduction 72 
Pseudomonas aeruginosa is a highly successful opportunistic gram-negative bacterium which is   73 
well adapted to the airway niche in cystic fibrosis (CF). P. aeruginosa is the dominant pathogen in 74 
the CF lung and is associated with increased morbidity and mortality in this population [1]. P. 75 
aeruginosa is intrinsically resistant to many classes of antibiotics, produces a host of virulence 76 
factors and forms impenetrable biofilms in the CF airways [2].   P. aeruginosa controls the production 77 
of these virulence factors using a cell-to-cell communication known as quorum sensing (QS) [3]. This 78 
allows the whole bacterial population to sense and respond to changes in environmental stimuli and 79 
to coordinate gene expression of the community as a whole.  80 
The P. aeruginosa QS system consists of 3 interlinking QS circuits, one of which is the pqs QS 81 
circuit.  The pqs QS systems uses multiple 2-alkyl-4 quinolones (AQs) as signal molecules, including 82 
the pseudomonas quinolone signal (PQS) molecule (2-heptyl-3-hydroxy-4(1H)-quinolone) and its 83 
precursor HHQ (2-heptyl-4-hydroxyquinoline) [4]. Both PQS and HHQ act as autoinducers to increase 84 
AQ biosynthesis [5] . In addition, PQS is crucial for the production of virulence factors and biofilm 85 
formation both in vitro and in animal models of infection [5]. P. aeruginosa produces over 50 AQs, 86 
and the roles of many of these AQs are not yet fully understood [6].   87 
Several AQs are detectable in the sputum and plasma of adults with CF and chronic pulmonary P. 88 
aeruginosa. Higher systemic concentrations of several AQs are associated with higher P. 89 
aeruginosa loads and lower lung function, in cross section analyses [7, 8]. This suggests that high 90 
systemic AQ levels may be associated with an adverse prognosis. In addition, systemic 91 
concentrations of several AQs decrease following intravenous anti-pseudomonal antibiotics, [8] 92 
suggesting they have potential as biomarkers of change in clinical status.  93 
We hypothesised that higher levels of AQs in the sputum and plasma of adults with CF would be 94 
associated with adverse long term clinical outcomes in this patient population.  95 
We investigated whether detection of six individual AQs in the sputum and plasma of people with 96 
CF could be linked to long-term outcomes, including death or lung transplantation, as well as annual 97 
rate of lung function decline and intravenous (IV) antibiotic use for pulmonary exacerbations. Clinical 98 
data over an 8 year period was retrospectively collected on 90 adults with CF who had previously 99 
participated in an AQ biomarker study [7].  100 
 101 
Methods 102 
Participants 103 
We studied 90 adults with CF who had previously participated in an AQ biomarker study, the full 104 
details of which were previously published [7]. In summary, participants were recruited at clinical 105 
stability from two UK adult CF centres between the years 2009 and 2011. Baseline demographic data 106 
and data on six AQs measured in both sputum and plasma samples were used [7].   107 
Study design 108 
Follow up clinical data were retrospectively obtained from the UK CF registry. Annual data were 109 
collected from the participants from the year of recruitment to the end of the study period in 2017. 110 
Data on death, lung transplantation, lung function and the number of IV antibiotic days for pulmonary 111 
exacerbations were obtained. The number of IV antibiotic days was measured annually from the year 112 
of recruitment to the end of 2017.  For lung function data, the best recorded forced expiratory volume 113 
in 1 s (FEV1) of the preceding year was used.  114 
The primary outcomes were death or lung transplantation during the follow up period. Secondary 115 
outcomes were the number of IV antibiotic days for pulmonary exacerbations and rate of decline in 116 
FEV1.  117 
Sample processing and AQ analysis 118 
All sample processing and AQ analyses were performed in the initial study as previously described 119 
[7]. Sputum plugs were harvested for quantitative AQ analyses [9, 10]. Venous blood samples were 120 
centrifuged at 1000 g for 15 min at 4°C, plasma was then separated and snap frozen in liquid nitrogen. 121 
Sputum samples for AQ analysis were extracted using acidified ethyl acetate (Fisher Chemicals, 122 
Loughborough, UK) [9, 10]. Plasma samples were extracted by solid phase extraction and plasma 123 
matrix matched samples from a healthy volunteer donor were prepared to allow calibration of samples. 124 
Prepared clinical samples for AQ analyses were subjected to liquid chromatography-tandem mass 125 
spectrometry  (LC-MS/MS) according to Ortori et al 2011 [9].  All samples were analysed once using 126 
LC-MS/MS with no replicate analysis performed.  127 
The lower limit of quantification (LLOQ) was established by using serial dilutions of the analyte mix 128 
and spiking into blank plasma samples prior to extraction and analysis, The LLOQ for plasma was 129 
defined as the analyte concentration at which a signal/noise ratio of 10:1 was achieved. In the absence 130 
of blank sputa to produce matrix matched calibration, 1.0mL aliquots of 0.9% NaCl were used and 131 
there was no LLOQ defined for sputum samples.  A total of six AQs were analysed individually: HHQ 132 
(2-heptyl-4-hydroxyquinoline), NHQ (2-nonyl-4-hydroxyquinoline),  PQS (2-heptyl-3-hydroxy-4(1H)-133 
quinolone), C9-PQS (2-nonyl-3-hydroxy-4(1H)-quinolone), HQNO (2-heptyl-4-hydroxyquinoline-N-134 
oxide) and NQNO (2-nonyl-4-hydroxyquinoline-N-oxide).  Calculated LLOQs in plasma samples were 135 
as follows: HHQ 10 pmol/L; NHQ 10 pmol/L; HQNO 30 pmol/L, NQNO 40 pmol/L; PQS 100 pmol/L 136 
and C9-PQS 100 pmol/L [7]. Quantitative concentrations for the six AQs both in plasma and sputum 137 
are summarised in Supplementary Table 2.  138 
Statistical Analysis 139 
The six measured AQs were analysed individually and combined detectable AQ levels in sputum and 140 
plasma were calculated.   141 
For initial analyses, individual AQ levels were classified as detectable or undetectable (concentrations 142 
above or below the LLOQ respectively). A binary measure of combined AQs was defined as a 143 
detection of at least one individual AQ in sputum or plasma respectively.  Two-sample Wilcoxon rank-144 
sum (Mann-Whitney) tests and Pearson’s chi-squared tests were used to assess binary AQ levels 145 
with the primary and secondary clinical outcomes.   146 
If significant associations were obtained using binary AQ analyses, further quantitative analyses were 147 
performed.  Individual AQ concentrations were then compared with clinical outcomes using Spearman 148 
rank correlation coefficients. Statistical significance was assessed as p<0.05. All data were analysed 149 
using Stata SE15 statistical software (Texas, USA).  150 
 151 
Results 152 
Of the 90 participants in the original study, 7 were lost during follow up and therefore 83 participants 153 
were included in the analyses.  Baseline characteristics are summarised in Table 1.  154 
The median follow up period was 6.3 years (IQR 5.6 to 6.7 years). During the follow up period, 23 155 
participants (27%) either died or had bilateral lung transplantation. Three people had a bilateral lung 156 
transplant and subsequently died during the follow up period.  These characteristics are summarised 157 
in Table 2.  158 
 159 
Table 1. Baseline clinical characteristics and P. aeruginosa status of participants. 160 
Variable      Baseline (n=83)  
Nottingham University Hospitals NHS trust      42   
University Hospitals Birmingham NHS 
Foundation Trust      41  
Age in years: median (range)     28.4 (17.8 to 61.5)  
Gender, males (%)     54 (65.1)  
FEV1 % predicted: mean (SD)     58 (±20)  
Absolute FEV1 in L: mean (SD)     2.13 (±0.9)  
BMI: mean (SD)     22.9 (± 3.3)  
P. aeruginosa status at baseline: n (%)    
Never  
 
   0 (0)  
Free     1 (1.2)  
Intermittent     2 (2.4)  
Chronic     80 (96.4)                                 
    
n = number of participants with data available; SD = standard deviation 
P. aeruginosa status of participants defined by Leeds criteria [11]  
 161 
 162 
 163 
 164 
 165 
Table 2. Summary of clinical data during follow up period.  166 
Variable N    (%) Outcome 
Follow up time¥ 83 100.0% 6.3 (5.6-6.7) 
Number of deaths/lung transplantation 23 27.7%  
Died during follow up 15 18.1%  
    
Rate of decline per year§:    
Absolute FEV1 (ml) 80 96.4% 53.1 (55.5) 
Percent predicted FEV1 (%) 80 96.4% 1.6 (2.0) 
    
Number of IV antibiotic days per year¥:    
Overall 81 97.6% 37.5 (16.4-58.7) 
No death/transplant 59 71.1% 31.9 (13.0-43.7) 
Death/transplant* 22 26.5% 60.1 (46.5-80.4) 
    
¥: reported as median and interquartile range. § reported as mean and standard deviation. *Mann-
Whitney significance p<0.001. IV= intravenous. N= number of participants with data available. 
 167 
 168 
Presence or absence of detectable levels of AQs at baseline on primary outcomes. 169 
Death or lung transplantation during follow up was not statistically different in the presence or absence 170 
of detectable levels of six individual AQs at baseline (Table 3), using binary AQ analyses (detected 171 
versus not detected). Similarly, there were no statistical associations between the combined AQs 172 
measured and primary outcomes, indicating indicating independence (chi-squared p=0.751 and p= 173 
0.351 for total sputum and plasma AQs respectively, Table 3).  174 
 175 
 176 
 177 
 178 
 179 
 180 
Table 3. Individual and combined total AQs with primary outcome of death or lung 181 
transplantation. 182 
AQ Death/transplant: n(%) No Death/transplant: n(%) p-value (chi²) 
Sp HHQ + 14 (70) 34 (65.4) 0.71 
Sp HHQ - 6 (30) 18 (34.6)  
Pl HHQ + 14 (66.7) 35 (58.3) 0.501 
Pl HHQ - 7 (33.3) 25 (41.7)  
Sp NHQ + 15 (75) 35 (67.3) 0.526 
Sp NHQ - 5 (25) 5 (32.7)  
Pl NHQ + 3 (14.3) 18 (30) 0.157 
Pl NHQ - 18 (85.7) 42 (70)  
Sp PQS + 12 (60) 31 (59.6) 0.98 
Sp PQS - 8 (40) 21 (40.4)  
Pl PQS + 8 (38.1) 20 (33.3) 0.693 
Pl PQS - 13 (61.9) 40 (66.7)  
Sp C9-PQS + 15 (75) 33 (63.5) 0.352 
Sp C9-PQS - 5 (25) 19 (36.5)  
Pl C9-PQS + 3 (14.3) 5 (8.3) 0.431 
Pl C9-PQS - 18 (85.7) 55 (91.7)  
Sp HQNO + 16 (80) 39 (75) 0.655 
Sp HQNO - 4 (20) 13 (25)  
Pl HQNO + 11 (52.4) 28 (46.7) 0.652 
Pl HQNO - 10 (47.6) 32 (53.3)  
Sp NQNO + 14 (70) 39 (75) 0.666 
Sp NQNO - 6 (30) 13 (25)  
Pl NQNO + 8 (38.1) 21 (35) 0.799 
Pl NQNO - 13 (61.9) 39 (65)  
Total Sp AQ+ 18 (90) 48 (92.3) 0.751 
Total Sp AQ - 2 (10) 4 (7.7)  
Total Pl AQ + 15 (71.4) 36 (60) 0.351 
Total Pl AQ - 6 (28.6) 24 (40)  
+ detected; - undetected; Sp=Sputum; Pl=Plasma; AQ=2-alkyl-4 quinolones; n= number; HHQ= 2-
heptyl-4-hydroxyquinoline; NHQ= 2-nonyl-4-hydroxyquinoline; PQS=2-heptyl-3-hydroxy-4(1H)-
quinolone; C9-PQS= 2-nonyl-3-hydroxy-4(1H)-quinolone; HQNO= 2-heptyl-4-hydroxyquinoline-N-
oxide; NQNO= 2-nonyl-4-hydroxyquinoline-N-oxide 
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 185 
 186 
 187 
The presence or absence of detectable levels of AQs at baseline on secondary outcomes 188 
There was no statistical difference demonstrated with rate of FEV1 decline both with individual and 189 
combined AQs detected in plasma or sputum (Supplementary Table 1).  190 
There was no association between five of the individual AQs and number of IV antibiotic days per 191 
year (Supplementary Table 1).   192 
The presence of C9-PQS in the sputum was associated with an increase in IV antibiotic days per year 193 
during the follow up period (Mann-Whitney p=0.011; Figure 1). The median number of IV antibiotic 194 
days per year if sputum C9-PQS was detected was 41.4 (IQR: 26.6 to 60.7) compared with 28.2 (IQR: 195 
4.0 to 44.4) when not detected. A similar finding was observed when follow up was restricted to 3 196 
years; 44.8 (IQR: 25.1 to 62.1) when sputum C9-PQS was detected compared with 29.7 (IQR: 4.7 to 197 
50.4) when not detected (Mann-Whitney p=0.046).  The concentration of C9-PQS in sputum was 198 
positively correlated with number of IV antibiotics per year but did not reach statistical significance 199 
(Spearman rank correlation; r= 0.2, p= 0.09; Supplementary Figure 1).  There was no statistical 200 
difference in the number of IV antibiotic days when C9-PQS was detected in plasma (Supplementary 201 
Table 1; Mann-Whitney p=0.32), nor detectable levels of total combined AQs in plasma or sputum 202 
(Supplementary Table 1).  The number of IV antibiotic days per year was statistically higher in people 203 
who died or had a bilateral lung transplantation in the follow up period (Mann-Whitney p<0.001, Table 204 
2). 205 
 206 
 207 
 208 
 209 
 210 
 211 
 212 
Figure 1. Annual number of IV antibiotic days according to C9-PQS detection at baseline. 213 
  214 
Figure 1 legend. Box plot showing the relationship between the presence and absence of detectable 215 
levels of sputum and plasma C9-PQS at baseline with the number of intravenous antibiotics days 216 
per year during the follow up period.  Box represents interquartile range, Line represents median 217 
value. C9-PQS= 2-nonyl-3-hydroxy-4(1H)-quinolone; IV= Intravenous; p value derived from Mann-218 
Whitney test; n= number of observations. 219 
 220 
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 222 
 223 
 224 
Discussion 225 
This is the first study to explore the relationship between baseline AQ quorum sensing signal 226 
molecules measured in sputum or plasma with long term outcomes in adults with CF. There were no 227 
significant difference between the detection of sputum or plasma AQs at baseline with death, lung 228 
transplantation or rate of FEV1 decline over the follow up period. One of the six AQs measured was 229 
associated with increased IV antibiotic usage in the follow up period. A higher number of IV antibiotic 230 
days for pulmonary exacerbations were observed in the presence of detectable levels of sputum 231 
C9-PQS. However, plasma levels of C9-PQS levels were not significantly associated with IV 232 
antibiotic usage. This may be explained by the low number of participants with detectable C9-PQS 233 
in plasma (eight adults compared to forty eight adults with detectable C9-PQS in sputum).  234 
There are a number of limitations in this study that should be considered when interpreting these 235 
data. This is a retrospective analysis and the number of participants who died or had lung 236 
transplantation resulted in small numbers. We primarily assessed AQ levels as dichotomous; 237 
detectable or not detectable, as the variability across the sample size would have provided low 238 
power.  Intra-subject variability of AQ concentrations is unknown and a single measure of AQ 239 
concentration may not reflect the longer period during which the AQs may influence disease 240 
progression. Whilst effect sizes are robust, findings are to be regarded as ‘hypothesis generating’ 241 
as significant p values may be a consequence of multiple hypothesis testing.  242 
 Despite limitations, these findings provide evidence of a possible association between both sputum 243 
and plasma C9-PQS levels and antibiotic usage, which should be confirmed through prospective 244 
study design.  245 
P. aeruginosa  is the major respiratory pathogen in people with CF and is difficult to eradicate from 246 
the CF airways as it is intrinsically resistant to many classes of antibiotics and forms antibiotic 247 
resistant biofilms [12]. The AQ class of quorum sensing molecules plays an important role in 248 
pathogenicity for P. aeruginosa and AQ deficient mutants show reduced virulence in infection 249 
models [13-15]. PQS and its immediate precursor HHQ are the major AQ signalling molecules in P. 250 
aeruginosa [16]. PQS regulates the expression of at least 182 genes including those that code for the 251 
iron-chelating siderophores, pyoverdine and pyochelin [17, 18] as well as playing a role in regulating 252 
antibiotic resistance and biofilm maturation [19-21]. In addition, PQS regulates the production of key 253 
virulence factors that are associated with pulmonary exacerbations such as elastase [22], pyocyanin 254 
[23] and cyanide [24]. Both C9-PQS and NHQ are as effective as their  C7 congeners PQS and 255 
HHQ at activating the AQ receptor PqsR  which further drives the autoinduction of  AQ biosynthesis 256 
and up regulates key virulence determinants [25]. Furthermore, molecular imaging techniques have 257 
shown that initial biofilm formation is marked by a dramatic increase in the production of C9-PQS, 258 
suggesting it may be important for the growth of P.aeruginosa in communities and early biofilm 259 
formation [26]. Although our current understanding of the role of C9-PQS is limited [27], it is 260 
biologically plausible that C9-PQS may be associated with increased antibiotic usage due to 261 
increased virulence factor production during pulmonary exacerbations.  262 
Recurrent severe pulmonary exacerbations are associated with both increased morbidity and 263 
mortality in CF [28]. In recent years, attempts to develop new classes of antimicrobial agents have 264 
included targeting of virulence factors or virulence regulatory mechanisms. Consequently, the AQ 265 
signalling system is a promising potential target for antimicrobial agents which do not kill the organism 266 
but instead block or attenuate the ability to cause disease. This is important as multiple courses of 267 
antibiotics are detrimental to the host and contribute to a growing global burden of multi-antibiotic 268 
resistance that needs to be addressed urgently.  269 
In conclusion, this hypothesis generating study showed an association between C9-PQS detected in 270 
the sputum and increased antibiotic usage in the CF population, which requires more comprehensive 271 
investigation to confirm or refute these findings. However, there were no other associations between 272 
the five AQs detected and adverse clinical outcomes measured.  There is much to learn about AQ 273 
regulation in the clinical setting, particularly as development of anti-virulence drugs that target PQS-274 
dependent QS pathways progresses [29].   275 
 276 
Author Contributions 277 
The study was designed by KW/HB/AF. KW collected the data. The analysis was performed by KW 278 
and IS. All authors contributed to data interpretation, data presentation and writing of the 279 
manuscript. All authors approved the final version of the manuscript. 280 
Declarations of Interest 281 
The University of Nottingham has a patent for the use of alkyl quinolones as biomarkers for P. 282 
aeruginosa infection (PCT/GB2014/051458). 283 
 284 
 285 
 286 
Funding 287 
Funding contributions from NIHR Nottingham Biomedical Research Centre and the U.K. Medical 288 
Research Council (grant number G0801558/1).  289 
 290 
References 291 
1. Emerson, J., et al., Pseudomonas aeruginosa and other predictors of mortality and 292 
morbidity in young children with cystic fibrosis. Pediatr Pulmonol, 2002. 34(2): p. 91-293 
100. 294 
2. Silva Filho, L.V.R.F.d., et al., Pseudomonas aeruginosa infection in patients with cystic 295 
fibrosis: scientific evidence regarding clinical impact, diagnosis, and treatment. Jornal 296 
brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e 297 
Tisilogia, 2013. 39(4): p. 495-512. 298 
3. Passos da Silva, D., et al., An Update on the Sociomicrobiology of Quorum Sensing in 299 
Gram-Negative Biofilm Development. Pathogens, 2017. 6(4). 300 
4. Pesci, E.C., et al., Quinolone signaling in the cell-to-cell communication system of 301 
Pseudomonas aeruginosa. Proc Natl Acad Sci U S A, 1999. 96(20): p. 11229-34. 302 
5. Rampioni, G., et al., Unravelling the Genome-Wide Contributions of Specific 2-Alkyl-4-303 
Quinolones and PqsE to Quorum Sensing in Pseudomonas aeruginosa. PLOS Pathogens, 304 
2016. 12(11): p. e1006029. 305 
6. Lepine, F., et al., Electrospray/mass spectrometric identification and analysis of 4-306 
hydroxy-2-alkylquinolines (HAQs) produced by Pseudomonas aeruginosa. J Am Soc Mass 307 
Spectrom, 2004. 15(6): p. 862-9. 308 
7. Barr, H.L., et al., Diagnostic and prognostic significance of systemic alkyl quinolones for 309 
P. aeruginosa in cystic fibrosis: A longitudinal study. J Cyst Fibros, 2017. 16(2): p. 230-310 
238. 311 
8. Barr, H.L., et al., Pseudomonas aeruginosa quorum sensing molecules correlate with 312 
clinical status in cystic fibrosis. European Respiratory Journal, 2015. 46(4): p. 1046-313 
1054. 314 
9. Ortori, C.A., et al., Simultaneous quantitative profiling of N-acyl-L-homoserine lactone 315 
and 2-alkyl-4(1H)-quinolone families of quorum-sensing signaling molecules using LC-316 
MS/MS. Anal Bioanal Chem, 2011. 399(2): p. 839-50. 317 
10. Ortori, C.A., et al., Comprehensive profiling of N-acylhomoserine lactones produced by 318 
Yersinia pseudotuberculosis using liquid chromatography coupled to hybrid quadrupole-319 
linear ion trap mass spectrometry. Anal Bioanal Chem, 2007. 387(2): p. 497-511. 320 
11. Lee, T.W., et al., Evaluation of a new definition for chronic Pseudomonas aeruginosa 321 
infection in cystic fibrosis patients. J Cyst Fibros, 2003. 2(1): p. 29-34. 322 
12. Galloway, W.R., et al., Quorum sensing in Gram-negative bacteria: small-molecule 323 
modulation of AHL and AI-2 quorum sensing pathways. Chem Rev, 2011. 111(1): p. 28-324 
67. 325 
13. Diggle, S.P., et al., The Pseudomonas aeruginosa quinolone signal molecule overcomes 326 
the cell density-dependency of the quorum sensing hierarchy, regulates rhl-dependent 327 
genes at the onset of stationary phase and can be produced in the absence of LasR. 328 
Molecular Microbiology, 2003. 50(1): p. 29-43. 329 
14. Cao, H., et al., A quorum sensing-associated virulence gene of &lt;em&gt;Pseudomonas 330 
aeruginosa&lt;/em&gt; encodes a LysR-like transcription regulator with a unique self-331 
regulatory mechanism. Proceedings of the National Academy of Sciences, 2001. 98(25): 332 
p. 14613. 333 
15. Déziel, E., et al., The contribution of MvfR to Pseudomonas aeruginosa pathogenesis and 334 
quorum sensing circuitry regulation: multiple quorum sensing-regulated genes are 335 
modulated without affecting lasRI, rhlRI or the production of N-acyl- l-homoserine 336 
lactones. Molecular Microbiology, 2005. 55(4): p. 998-1014. 337 
16. Chan, K.-G., Y.-C. Liu, and C.-Y. Chang, Inhibiting N-acyl-homoserine lactone synthesis 338 
and quenching Pseudomonas quinolone quorum sensing to attenuate virulence. Frontiers 339 
in Microbiology, 2015. 6(1173). 340 
17. Bredenbruch, F., et al., The Pseudomonas aeruginosa quinolone signal (PQS) has an 341 
iron-chelating activity. Environmental Microbiology, 2006. 8(8): p. 1318-1329. 342 
18. Diggle, S.P., et al., The Pseudomonas aeruginosa 4-Quinolone Signal Molecules HHQ and 343 
PQS Play Multifunctional Roles in Quorum Sensing and Iron Entrapment. Chemistry & 344 
Biology, 2007. 14(1): p. 87-96. 345 
19. Diggle, S.P., et al., The Pseudomonas aeruginosa quinolone signal molecule overcomes 346 
the cell density-dependency of the quorum sensing hierarchy, regulates rhl-dependent 347 
genes at the onset of stationary phase and can be produced in the absence of LasR. Mol 348 
Microbiol, 2003. 50(1): p. 29-43. 349 
20. Gallagher, L.A., et al., Functions required for extracellular quinolone signaling by 350 
Pseudomonas aeruginosa. J Bacteriol, 2002. 184(23): p. 6472-80. 351 
21. Cao, H., et al., A quorum sensing-associated virulence gene of Pseudomonas aeruginosa 352 
encodes a LysR-like transcription regulator with a unique self-regulatory mechanism. 353 
Proc Natl Acad Sci U S A, 2001. 98(25): p. 14613-8. 354 
22. Jaffar-Bandjee, M.C., et al., Production of elastase, exotoxin A, and alkaline protease in 355 
sputa during pulmonary exacerbation of cystic fibrosis in patients chronically infected by 356 
Pseudomonas aeruginosa. J Clin Microbiol, 1995. 33(4): p. 924-9. 357 
23. Mowat, E., et al., Pseudomonas aeruginosa Population Diversity and Turnover in Cystic 358 
Fibrosis Chronic Infections. American Journal of Respiratory and Critical Care Medicine, 359 
2011. 183(12): p. 1674-1679. 360 
24. Anderson, R.D., et al., Biosignificance of bacterial cyanogenesis in the CF lung. Journal of 361 
Cystic Fibrosis, 2010. 9(3): p. 158-164. 362 
25. Ilangovan, A., et al., Structural basis for native agonist and synthetic inhibitor 363 
recognition by the Pseudomonas aeruginosa quorum sensing regulator PqsR (MvfR). 364 
PLoS pathogens, 2013. 9(7): p. e1003508-e1003508. 365 
26. Baig, N.F., et al., Multimodal chemical imaging of molecular messengers in emerging 366 
Pseudomonas aeruginosa bacterial communities. The Analyst, 2015. 140(19): p. 6544-367 
6552. 368 
27. Fletcher, M.P., et al., A dual biosensor for 2-alkyl-4-quinolone quorum-sensing signal 369 
molecules. Environmental Microbiology, 2007. 9(11): p. 2683-2693. 370 
28. Ellaffi, M., et al., One-year outcome after severe pulmonary exacerbation in adults with 371 
cystic fibrosis. Am J Respir Crit Care Med, 2005. 171(2): p. 158-64. 372 
29. Williams, P. and M. Cámara, Quorum sensing and environmental adaptation in 373 
Pseudomonas aeruginosa: a tale of regulatory networks and multifunctional signal 374 
molecules. Current Opinion in Microbiology, 2009. 12(2): p. 182-191. 375 
 376 
